Amylyx Pharmaceuticals (AMLX) Inventory (2022 - 2023)
Amylyx Pharmaceuticals' (AMLX) quarterly Inventory came in at $38.3 million in Q4 2023, up 292.29% year-on-year from $9.8 million in Q4 2022, and up 18.38% quarter-over-quarter from $32.4 million in Q3 2023.
Amylyx Pharmaceuticals (AMLX) Inventory (2022 - 2023) Analysis & Trends
Amylyx Pharmaceuticals' Inventory history runs 2 years deep, the most recent figure standing at $38.3 million for Q4 2023.
- On a quarterly basis, Inventory rose 292.29% year-over-year to $38.3 million in Q4 2023; TTM through Dec 2023 was $38.3 million, a 292.29% increase from a year earlier, with the FY2023 full-year figure at $38.3 million, up 292.29% from the prior year.
- Inventory grew to $38.3 million in Q4 2023 per AMLX's latest filing, from $32.4 million in the prior quarter.
- Across five years, Inventory topped out at $38.3 million in Q4 2023 and bottomed at $563000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.36 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.18 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.55 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 8.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 178.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.49 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.93 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 64.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.72 Bn |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 38.32 Mn |
| Sep 30, 2023 | 32.37 Mn |
| Jun 30, 2023 | 24.86 Mn |
| Mar 31, 2023 | 13.08 Mn |
| Dec 31, 2022 | 9.77 Mn |
| Sep 30, 2022 | 563,000.00 |